Experimental vaccine targets brain metastases in first human trial

This early-phase study tests whether a special vaccine (SV-BR-1-GM) combined with an immunotherapy drug (pembrolizumab) is safe and feasible for people with solid tumors that have spread to the brain or spinal cord. About 20 adults whose cancer has worsened despite standard treatments will receive up to nine cycles of the combination. The main goals are to check for serious side effects and see how many patients can complete six months of therapy.